Related Experiment Video

Updated: Jul 14, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells

Xiao Wang1, Libin Zhou, Li Shao

  • 1Shanghai Institute of Endocrine and Metabolic Diseases, Department of Endocrine and Metabolic Diseases, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.

Life Sciences
|June 5, 2007
PubMed

Insights

Troglitazone activates AMP-activated protein kinase (AMPK) in beta cells, initially inhibiting insulin secretion. Long-term treatment may improve glucose-stimulated insulin secretion, protecting cells from glucolipotoxicity.

Area of Science:

  • Biochemistry
  • Cell Biology
  • Endocrinology

Background:

  • AMP-activated protein kinase (AMPK) activity is crucial for regulating insulin secretion.
  • Troglitazone is known to reduce serum insulin levels and preserve beta cell function.
  • Understanding troglitazone's direct impact on beta cell AMPK activity and insulin secretion is important.

Purpose of the Study:

  • To investigate the effects of troglitazone on AMPK activity and insulin secretion in beta cells.
  • To determine the impact of short-term versus long-term troglitazone exposure.

Main Methods:

  • Isolated rat islets and MIN6 cells were utilized.
  • Cells were exposed to troglitazone for short (1 hour) and long (20 hours) durations.
  • AMPK activity, acetyl-CoA carboxylase phosphorylation, and insulin secretion were measured.

Main Results:

  • Short-term troglitazone treatment activated AMPK and suppressed glucose-stimulated insulin secretion (GSIS).
  • Combined glucose and palmitate-stimulated insulin secretion was also inhibited by short-term treatment.
  • Long-term treatment led to sustained AMPK and acetyl-CoA carboxylase phosphorylation, with increased GSIS post-treatment.
  • Troglitazone demonstrated direct inhibition of insulin hypersecretion induced by high glucose and fatty acids.

Conclusions:

  • Troglitazone directly activates AMPK within beta cells.
  • The drug offers protection against glucolipotoxicity by mitigating insulin hypersecretion.
  • Troglitazone exhibits both peripheral insulin-sensitizing effects and direct beta cell protective actions.

More Related Videos

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...